Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on January 25, 2017, 10:08:21 am
-
Gilead Sciences’ experimental fixed-dose combination tablet sofosbuvir/velpatasvir/voxilaprevir performed very well among those with all six genotypes of hepatitis C virus (HCV) who had failed a previous regimen. The new regimen, given for 12 weeks, has the same components of the approved tablet Epclusa (sofosbuvir/velpatasvir) and adds the experimental voxilaprevir.
The double-blind, placebo-controlled Phase III POLARIS-1 study included 415 people with genotypes 1 through 6 of hep C at 109 sites in seven Western nations. They had all previously been treated with the class of hep C drugs known as NS5A inhibitors.
For more...
https://www.hepmag.com/article/excellent-results-gileads-experimental-regimen-hep-c-genotypes